Article
The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis.
Genes and immunity - 1 Feb 2019
Watts Laura, Karaderi Tugce, Roberts Amity, Appleton Louise, Wordsworth Tom, Cohen Carla, Wordsworth Paul, Vecellio Matteo
Abstract excerpt
Genetic polymorphism (rs1800693) of TNFRSF1A (type 1 tumour necrosis factor receptor) encodes a potentially anti-inflammatory soluble truncated form of the p55 receptor, which is associated with predisposition to multiple sclerosis but protection against ankylosing spondylitis (AS). We analysed 2917 UK Caucasian cases by linear and logistic regression for associations of rs1800693 with disease severity assessed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.